COMMUNIQUÉS West-GlobeNewswire

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
10/09/2026
TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully priced its offering of approximately $4.9 billion ( [...]
Ethris and EIB sign €30M financing under HERA Invest to advance further clinical development of broad-spectrum nasal antiviral
10/09/2026
Funding will support Ethris in the development of its portfolio of respiratory mRNA products for chronic respiratory diseases and pandemic preparedness. EIB’s financing is backed up by DG HERA, as part of the European [...]
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
10/09/2026
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) Filing acceptance is based on the Phase III METEOROID study showing [...]
VVMF, Australia's First Viral Vector CDMO Receives TGA Manufacturing Licence
10/09/2026
Regulatory milestone strengthens Australia’s sovereign advanced therapeutics manufacturing capability SYDNEY, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first [...]
Hexiris Ophthalmics to Present First-in-Human OBi Glaucoma Data at Five Fall Meetings, Beginning with the Ophthalmology Futures Forum in London
10/09/2026
Physician-founded company will bring its office-based interventional glaucoma platform to Ophthalmology Futures, ESCRS, Sally Letson, CGS and AAO 2026 DIEPPE, New Brunswick, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Hexiris [...]
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
10/09/2026
€3.1 million financing led by new investor Clave Capital, with participation from existing investors Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data readout [...]
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
10/09/2026
Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients DISC-3405 is the first monoclonal [...]
Zoher F. Kapasi, PhD, PT, Named Provost of Thomas Jefferson University
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Thomas Jefferson University has announced the appointment of Zoher F. Kapasi, PhD, PT, as its next Provost effective Nov. 1, 2026. With extensive experience in higher [...]
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
09/09/2026
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the [...]
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
09/09/2026
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in [...]
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
09/09/2026
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/09/2026
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Century Therapeutics Appoints Joseph Truitt to Board of Directors
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
09/09/2026
Board Unanimously Concludes to Retain CooperSurgical Expands Share Repurchase Authorization from $2 billion to $3 billion Board Remains Open to All Value Options that Create Shareholder Value SAN RAMON, Calif., Sept. 09 [...]
NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
09/09/2026
PARIS and CAMBRIDGE, Mass., 09 sept. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]
Crescent Biopharma Announces Grants of Inducement Awards
09/09/2026
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
CooperCompanies Announces Third Quarter 2026 Results
09/09/2026
SAN RAMON, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2026. Revenue [...]

Pages